News | April 15, 2021

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application...

News | April 6, 2021

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic Data...

News | March 30, 2021

BrightInsight Announces $101M in Series C Funding led by General Catalyst The Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechSAN JOSE, Calif., March 30, 2021 – BrightInsight, Inc.,...

News | March 25, 2021

Edgewise Therapeutics Announces Pricing of Initial Public Offering BOULDER, Colo.–(BUSINESS WIRE)– Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies...

News | March 16, 2021

BrightInsight and AstraZeneca Collaborate to Enhance Disease Management BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant Environment SAN JOSE, Calif., March 16, 2021 – BrightInsight, Inc.,...

News | March 2, 2021

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China London and Research Triangle Park, N.C., and Shanghai and Princeton, N.J., March 2, 2021 – ReViral Ltd., a clinical-stage biopharmaceutical...